From: Optimizing palliative chemotherapy for advanced invasive mucinous adenocarcinoma of the lung
Characteristics | All (n = 79) |
---|---|
Chemotherapy line, n (%) | |
 First line | 19 (24.1) |
 Second line | 24 (30.4) |
 Third line | 21 (26.6) |
 Forth line | 15 (19.0) |
Chemotherapy cycle, median [interquartile range] | |
 First line | 4.0 [2.0–10.0] |
 Second line | 4.0 [2.0–8.0] |
 Third line | 4.0 [2.0–7.5] |
Conventional chemotherapy regimen, n (%) | |
 Platinum & Pemetrexed | 40 (50.6) |
 Platinum & Gemcitabine | 30 (38.0) |
 Platinum & Taxane | 5 (6.3) |
 Pemetrexed | 27 (34.2) |
 Gencitabine | 9 (11.4) |
 Taxane | 14 (17.7) |
 Navelbine | 12 (15.2) |
 Othersa | 7 (8.9) |
Targeted therapy, n (%) | 13 (16.5) |
 EGFR-TKI | 8 (10.1) |
 ALK-TKI | 4 (5.1) |
 Other TKIb | 1 (1.3) |
Immunotherapy, n (%) | 18 (22.8) |
 Nivolumab | 7 (8.9) |
 Pembrolizumab | 3 (3.8) |
 Atezolizumab | 4 (5.1) |
 Duvalumab | 2 (2.5) |
 Avelumab | 1 (1.3) |
 Other immunotherapiesc | 3 (3.8) |